Tarsus Pharmaceuticals, Inc. (TARS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Tarsus Pharmaceuticals, Inc. (TARS) closed at USD 72.29 on 2026-10-14, a change of +7 % over the past year, with a market capitalization of USD 3.32B.

Tarsus Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Tarsus Pharmaceuticals, Inc. key figures

Previous close

USD 72.29 (2026-10-14)

1-year change

+7 %

Market cap

USD 3.32B

Enterprise value

USD 2.75B

P/E ratio (trailing)

-65.73

P/E ratio (forward)

-258.15

EPS (trailing)

-1.08

EPS (forward)

-0.28

PEG ratio

n/a

Price to book

8.86

Revenue growth

69.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.31

Employees

370

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Tarsus Pharmaceuticals, Inc. and compare it with other stocks.